GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

Purpose

A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.

Conditions

  • Aortic Arch Dissection
  • Aortic Arch Aneurysm

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements. 2. Patient has been or is intended to be treated with the TBE Device in Zone 0 or Zone 1. 3. Patient is age ≥ 18 years at time of informed consent signature.

Exclusion Criteria

  1. Patient who is, at the time of consent, unlikely to be available for defined follow-up visits. 2. Patient with exclusion criteria required by local law. 3. Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study within 12 months of study enrollment. Subjects cannot be enrolled in another Gore study.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
GORE® TAG® Thoracic Branch Endoprosthesis (TBE)
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device)
  • Device: GORE® TAG® Thoracic Branch Endoprosthesis
    Lesions in aortic arch in Zone 0 or Zone 1

Recruiting Locations

HonorHealth
Scottsdale, Arizona 85251
Contact:
Hasan Aldailami, MD
480-246-3000
haldailami@honorhealth.com

Keck Medical Center of USC
Los Angeles, California 90033
Contact:
Sukgu Han, MD
323-442-5849
sukgu.han@med.usc.edu

Hartford Hospital
Hartford, Connecticut 06102
Contact:
Akhilesh Jain, MD
860-522-4158
akhilesh.jain@hhchealth.org

MedStar Washington Hospital Center
Washington D.C., District of Columbia 20010
Contact:
William Yoon, MD
202-877-5975
william.j.yoon@medstar.net

University of Florida Health Heart & Vascular
Gainesville, Florida 32608
Contact:
Martin Back, MD
352-273-5484
martin.back@surgery.ufl.edu

Lakeland Regional Medical Center
Lakeland, Florida 33805
Contact:
Mohammed Hassan, MD
863-413-5969
mohammed.hassan@mylrh.org

University of South Florida
Tampa, Florida 33606
Contact:
Halim Yammine, MD
813-821-8034
hyammine@usf.edu

University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27599
Contact:
Mark Farber, MD
919-966-3391
mark_farber@med.unc.edu

Duke University Medical Center
Durham, North Carolina 27710
Contact:
G. Chad Hughes IV, MD
919-668-0903
gchad.hughes@duke.edu

Thomas Jefferson University
Philadelphia, Pennsylvania 19107
Contact:
Cecilia Chin, MD
617-835-9038
cecillia.chin@jefferson.edu

The Methodist Hospital-Houston
Houston, Texas 77030
Contact:
Marvin Atkins, MD
713-441-5200
mdatkins@houstonmethodist.org

Baylor Scott & White Research Institute
Plano, Texas 75093
Contact:
Justin Schaffer, MD
469-800-6200
justin.schaffer@bswhealth.org

Intermountain Medical Center
Murray, Utah 84107
Contact:
Jane He, MD
801-507-4700
jane.he@imail2.org

University of Washington Medical Center
Seattle, Washington 98195
Contact:
Matthew Sweet, MD
206-598-8487
mpsweet@uw.edu

University of Wisconsin - Madison
Madison, Wisconsin 53792
Contact:
Kyla Bennett, MD
608-265-4420
bennettk@surgery.wisc.edu

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Peter Rossi, MD
414-955-1800
prossi@mcw.edu

More Details

Status
Recruiting
Sponsor
W.L.Gore & Associates

Study Contact

DeAnne Hart
800-437-8181
tbe25-03@wlgore.com

Detailed Description

Minimum of 125 total subjects with a TBE Device implantation procedure initiated in up to 50 Sites in the United States. Subjects will have follow-up at 1 Month, 6 Month, 1 Year, and annually thereafter for a minimum of 5-years and up to a maximum of 10 years.